Vascular Dementia
Conditions
Keywords
Herbal therapy, Randomized controlled trial, Vascular Dementia
Brief summary
The study will be a 24-week multicentre, double-blind, placebo-controlled phase Ⅱa trial with 4 treatment arms in China. Participants aged 55-80 years will be randomized to TMBCZG-high dose(84mg per day), TMBCZG- medium dose(56mg per day), TMBCZG- low dose(28mg per day) or to placebo. The primary endpoint will be VADAS-Cog and CDR-SB. Secondary outcomes included changes in MMSE and ADL. Patients' safety will be assessed by recording of adverse events, clinical examinations, electrocardiography and laboratory tests. The patients, caregivers, and investigators will be blinded to the treatment allocations.
Interventions
DRUGTMBCZG
0.1g per pill which contains 14mg TMBCZG
OTHERplacebo
0.1g per pill which contains 0mg TMBCZG
Sponsors
Beijing Union pharmaceutical factory II
Beijing Compete Medical Technology Development Co. Ltd.
Dongzhimen Hospital, Beijing
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
55 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Patients meeting the clinical diagnosis of probable vascular dementia(VaD) established according to the National Institute of Neurological Disorders and Stroke and the Association Internationale pour la Recherche et l'Enseignement en Neurosciences (NINDS-AIREN)were eligible to participate: 1. Dementia defined by clinical core criteria, 2. Cerebrovascular disease, defined by history of stroke, as well as multiple basal ganglia and white matter lacunes, or extensive periventricular white matter lesions( excluded medial temporal lobe atrophy or other special image), 3. A relationship between dementia and Cerebrovascular disease, manifested or inferred by the presence of one or more of the following: (a) onset of dementia within 3 months following a recognized stroke; (b) abrupt deterioration in cognitive functions; or fluctuating, stepwise progression of cognitive deficits. * Mild to Moderate Dementia with MMSE score of ≤26 and ≥11; * Aged ≥55 and ≤80 years old in both gender; * Weighing of ≥45kg and ≤90kg; * Adequate vision and hearing ability to complete all study tests; * With a stable caregiver. * Have a certain level of language competence (can read simple articles and write simple sentences); * Informed consent, signed informed consent by legal guardian.
Exclusion criteria
* A medical history of other dementia types, like mixed dementia, Alzheimer's disease, frontotemporal dementia, Parkinson's disease dementia, dementia with Lewy bodies, Huntington disease, et al; * Subdural hematoma, traffic hydrocephalus, brain tumor, thyroid disease,vitamin deficiency or other diseases which can lead to cognitive impediment; * Major depression (HAMD≥17) or major anxious(HAMA≥12); * Subject can't complete related test due to severe neurologic deficits, such as hemiplegia, aphasia, audio-visual disorder and so forth; * Severe cardiovascular disease(severe arrhythmia, myocardial infarction within 3 months, New York Heart Association Functional Classification III-IV, systolic pressure≥180mmHg or ≤90mmHg); * Severe liver or kidney dysfunction (alanine aminotransferase or aspartate transaminase is more than 1.5 times the upper limit of normal, or serum creatinine is more than the upper limit of normal); * Uncontrolled diabetes(glycosylated hemoglobin is more than 2 times the upper limit of normal); * Asthma, chronic obstructive pulmonary disease, multiple neuritis, myasthenia gravis and muscle atrophy; * Severe indigestion, gastrointestinal obstruction, gastric and duodenal ulcers and other gastrointestinal disorders that can affect drug absorption; * A medical history of epileptic history, glaucoma, alcoholism, or psycho-substance abuse; * Subject has been taking cholinesterase inhibitors, memantine, nimodipine or herbal medicine with function of improving cognition in the past one month; * Use of sympathomimetic or antihistamines drugs within 48h before assessment; * Allergic constitution or allergic reactions to experimental drug; * According to the assessment of the investigator, subject cann't complete the study due to poor compliance or other reasons; * Subject is participating in other clinical trials or participated in the past 1 month.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Vascular Dementia Assessment Scale-cognitive subscale(VADAS-Cog) | baseline, 4-week, 12-week, 24-week and 28-week. | Change from baseline to end of double-blind treatment of VADAS-Cog. |
| Clinical Dementia Rating-Sum of Boxes (CDR-SB) | baseline, 4-week, 12-week, 24-week and 28-week. | Change from baseline to end of double-blind treatment of CDR-SB. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mini-Mental State Examination (MMSE) | baseline, 4-week, 12-week, 24-week and 28-week. | Change from baseline to end of double-blind treatment of MMSE. |
| Activities of daily living (ADL) | baseline, 4-week, 12-week, 24-week and 28-week. | Change from baseline to end of double-blind treatment of ADL. |
Countries
China
Outcome results
None listed